FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/01/078843 [Registered on: 16/01/2025] Trial Registered Prospectively
Last Modified On: 30/12/2024
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Ayurveda 
Study Design  Randomized, Parallel Group, Active Controlled Trial 
Public Title of Study   Dronapuspi (Leucas cephalotes) for peptic ulcer disease healing. 
Scientific Title of Study   Exploring the ulcer healing potential of Dronapuspi (Leucas cephalotes) in parinamshoola (peptic ulcer disease) : A preclinical and clinical study 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Amit Kumar Taraphder 
Designation  Professor, Dept. of Dravyaguna Vijnana, IPGAE&R at SVSP. 
Affiliation  Institute of Post Graduate Ayurvedic Education and Research at S.V.S.P. 
Address  Dept. of Dravyaguna Vijnana, Room No. T2, Institute of Post Graduate Ayurvedic Education and Research at S.V.S.P. 294/3/1, A.P.C. Road ,Kolkata. West Bengal-700009.

Kolkata
WEST BENGAL
700009
India 
Phone  9874849650  
Fax    
Email  atipgaer@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Amit Kumar Taraphder 
Designation  Professor, Dept. of Dravyaguna Vijnana, IPGAE&R at SVSP. 
Affiliation  Institute of Post Graduate Ayurvedic Education and Research at S.V.S.P. 
Address  Dept. of Dravyaguna Vijnana, Room No. T2, Institute of Post Graduate Ayurvedic Education and Research at S.V.S.P. 294/3/1, A.P.C. Road ,Kolkata. West Bengal-700009.

Kolkata
WEST BENGAL
700009
India 
Phone  9874849650  
Fax    
Email  atipgaer@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Trisha Mukhopadhyay 
Designation  M.D. Scholar Dept. of Dravyaguna Vijnana IPGAE&R at S.V.S.P.. 
Affiliation  Institute of Post Graduate Ayurvedic Education and Research at S.V.S.P. 
Address  Dept. of Dravyaguna Vijnana, Room No. T2, Institute of Post Graduate Ayurvedic Education and Research at S.V.S.P. 294/3/1, A.P.C. Road ,Kolkata. West Bengal-700009.

Kolkata
WEST BENGAL
700009
India 
Phone  7439792282  
Fax    
Email  tutimukherjee@gmail.com  
 
Source of Monetary or Material Support  
Institute of Post Graduate Ayurvedic Education and Research at SVSP Hospital, Govt. of West Bengal. 294/3/1 A.P.C. Road Kolkata 700009. 
 
Primary Sponsor  
Name  Institute of Post Graduate Ayurvedic Education and Research at S.V.S.P.  
Address  294/3/1 A.P.C. Road, Kolkata- 700009 
Type of Sponsor  Government medical college 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
DR AMIT TARAPHDAR  Institute Of Post Graduate Ayurvedic Education and Research at S.V.S.P. Hospital  Room No. T2, Dept. of Dravyaguna 294/3/1, A.P.C. Road, Kolkata, 700009. Kolkata, West Bengal
Kolkata
WEST BENGAL 
9874849650

atipgaer@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
INSTITUTIONAL CLINICAL ETHICAL COMMITTEE , I.P.G.A.E.&R., KOLKATA  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition:K277||Chronic peptic ulcer, site unspecified, without hemorrhage or perforation. Ayurveda Condition: PARINAMASULAH,  
 
Intervention / Comparator Agent  
snoIntervention/ComparatorTypeDrug-TypeProcedure NameDetails
1Intervention ArmDrugClassical(1) Medicine Name: DRONAPUSPI, Reference: SAHASRA YOGA, Route: Oral, Dosage Form: Kwatha/ Kashaya, Dose: 30(ml), Frequency: bd, Bhaishajya Kal: Abhakta, Duration: 30 Days, anupAna/sahapAna: No, Additional Information:
2Comparator Arm (Non Ayurveda)-SUCRALFATESUCRAL FATE IN SUSPENSION FORM - 10ML TWICE A DAY AFTER MEAL AT NOON AND AT NIGHT FOR 30 DAYS.
 
Inclusion Criteria  
Age From  20.00 Year(s)
Age To  60.00 Year(s)
Gender  Both 
Details  Patients suffering from-
i) Feeling very full or bloated after a meal.
ii) Persistant heartburn.
iii) Feeling nausea
iv) Vomiting.  
 
ExclusionCriteria 
Details  i) Bleeding inside intestines.
ii) Perforation of intestinal wall.
iii) Haematemesis.
iv) Pregnant women.
v) Lactating mother.
vi)Malignancy
vii) age greater than 60 years and lesser than 20 years. 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Case Record Numbers 
Blinding/Masking   Participant Blinded 
Primary Outcome  
Outcome  TimePoints 
To assess the ulcer healing property of dronapuspi by monitoring the symptoms and signs of patients suffering from peptic ulcer disease.   30 days. 
 
Secondary Outcome  
Outcome  TimePoints 
Effect of test drug on quality of life among the patients suffering from peptic ulcer disease.  30 days. 
 
Target Sample Size   Total Sample Size="20"
Sample Size from India="20" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 2/ Phase 3 
Date of First Enrollment (India)   29/01/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="0"
Months="8"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary   This clinical study, which will take place at OPD of the IPGAE&R at SVSP Hospital, is a randomized, parallel-grouped control trial of a test drug comparing the efficacy of Sucral fate for 30 days in 20 patients with peptic ulcer disease. The primary outcome of this research is to evaluate the therapeutic efficacy of the test drug for its potential ulcer healing property in managing peptic ulcer disease. The secondary outcome is to determine the safety of the Test drug on quality of life among the patients suffering from peptic ulcer disease. 
Close